Clinical Trials
25 trialsCombination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
Dasatinib In Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
OHSU Knight Cancer Institute
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Northwestern University
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
BMS-CA180105
University of California, San Diego
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Massachusetts General Hospital
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Treatment of Adult Ph+ LAL With BMS-354825
Gruppo Italiano Malattie EMatologiche dell'Adulto
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Bristol-Myers Squibb